| Dr Mona Alipour, MD | |
|
4234 Riverwalk Pkwy Ste 230, Riverside, CA 92505-3312 | |
| (951) 781-3672 | |
| Not Available |
| Full Name | Dr Mona Alipour |
|---|---|
| Gender | Female |
| Speciality | Critical Care (intensivists) |
| Experience | 10 Years |
| Location | 4234 Riverwalk Pkwy Ste 230, Riverside, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053709071 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | A149540 (California) | Secondary |
| 207RC0200X | Internal Medicine - Critical Care Medicine | A149540 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Riverside Community Hospital | Riverside, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| El-bershawi Medical Corp | 9032298492 | 39 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida.
The Wall Street Journal writes how the health law's coverage expansions could provide entrepreneurs with a new source for health coverage.
New research appearing online today in Blood, the Journal of the American Society of Hematology (ASH), suggests that long-term survivors of hematopoietic cell transplants (HCT) are at an increased risk of developing heart disease risk factors such as high blood pressure, diabetes, and high cholesterol when compared to the general population.
Fat progenitor cells may contribute to cancer growth by fortifying the vessels that provide needed blood to tumors, according to preclinical research findings by investigators at The University of Texas Health Science Center at Houston (UTHealth).
In light of the recent launch of USAID's "Feed the Future" initiative, the Washington Post features a Q&A with Rajiv Shah, the administrator of the agency. The interview addresses what the program will look like on the ground, the focus on female farmers and related topics (Sheridan, 6/7).
› Verified 1 days ago
| Entity Name | El-bershawi Medical Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386813103 PECOS PAC ID: 9032298492 Enrollment ID: O20080509000414 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida.
The Wall Street Journal writes how the health law's coverage expansions could provide entrepreneurs with a new source for health coverage.
New research appearing online today in Blood, the Journal of the American Society of Hematology (ASH), suggests that long-term survivors of hematopoietic cell transplants (HCT) are at an increased risk of developing heart disease risk factors such as high blood pressure, diabetes, and high cholesterol when compared to the general population.
Fat progenitor cells may contribute to cancer growth by fortifying the vessels that provide needed blood to tumors, according to preclinical research findings by investigators at The University of Texas Health Science Center at Houston (UTHealth).
In light of the recent launch of USAID's "Feed the Future" initiative, the Washington Post features a Q&A with Rajiv Shah, the administrator of the agency. The interview addresses what the program will look like on the ground, the focus on female farmers and related topics (Sheridan, 6/7).
› Verified 1 days ago
| Entity Name | Pulmonary Consultants And Wellness Center Inc Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427440304 PECOS PAC ID: 9830418342 Enrollment ID: O20150505002252 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida.
The Wall Street Journal writes how the health law's coverage expansions could provide entrepreneurs with a new source for health coverage.
New research appearing online today in Blood, the Journal of the American Society of Hematology (ASH), suggests that long-term survivors of hematopoietic cell transplants (HCT) are at an increased risk of developing heart disease risk factors such as high blood pressure, diabetes, and high cholesterol when compared to the general population.
Fat progenitor cells may contribute to cancer growth by fortifying the vessels that provide needed blood to tumors, according to preclinical research findings by investigators at The University of Texas Health Science Center at Houston (UTHealth).
In light of the recent launch of USAID's "Feed the Future" initiative, the Washington Post features a Q&A with Rajiv Shah, the administrator of the agency. The interview addresses what the program will look like on the ground, the focus on female farmers and related topics (Sheridan, 6/7).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mona Alipour, MD Po Box 743892, Los Angeles, CA 90074-3892 Ph: (951) 781-3672 | Dr Mona Alipour, MD 4234 Riverwalk Pkwy Ste 230, Riverside, CA 92505-3312 Ph: (951) 781-3672 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida.
The Wall Street Journal writes how the health law's coverage expansions could provide entrepreneurs with a new source for health coverage.
New research appearing online today in Blood, the Journal of the American Society of Hematology (ASH), suggests that long-term survivors of hematopoietic cell transplants (HCT) are at an increased risk of developing heart disease risk factors such as high blood pressure, diabetes, and high cholesterol when compared to the general population.
Fat progenitor cells may contribute to cancer growth by fortifying the vessels that provide needed blood to tumors, according to preclinical research findings by investigators at The University of Texas Health Science Center at Houston (UTHealth).
In light of the recent launch of USAID's "Feed the Future" initiative, the Washington Post features a Q&A with Rajiv Shah, the administrator of the agency. The interview addresses what the program will look like on the ground, the focus on female farmers and related topics (Sheridan, 6/7).
› Verified 1 days ago
Sang Kun Yim, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 7117 Brockton Ave, Riverside, CA 92506 Phone: 951-683-6370 | |
Sarah Chae, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 4646 Brockton Ave Ste 201, Riverside, CA 92506 Phone: 951-585-1800 Fax: 951-585-1801 | |
Alina S Popa, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 4445 Magnolia Ave, Riverside, CA 92501 Phone: 951-788-3636 | |
Richard M. Bradburne, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 10800 Magnolia Ave, Riverside, CA 92505 Phone: 909-353-2000 | |
Shelly C. Thio, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 10800 Magnolia Ave, Riverside, CA 92505 Phone: 909-353-2000 | |
Fawaz Gailani, MD Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 10800 Magnolia Ave, Riverside, CA 92505 Phone: 909-353-2000 | |
Andrew Duke, M.D. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 4445 Magnolia Ave, Riverside, CA 92501 Phone: 951-788-3000 |